Acute lymphoblastic leukemia and down syndrome: 6-mercaptopurine and methotrexate metabolites during maintenance therapy

on behalf of the Nordic Society of Paediatric Haematology and Oncology (NOPHO)

doi:10.1038/s41375-020-0946-2

Acute lymphoblastic leukemia and down syndrome: 6-mercaptopurine and methotrexate metabolites during maintenance therapy

on behalf of the Nordic Society of Paediatric Haematology and Oncology (NOPHO)

Research related

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Original language	English
Pages (from-to)	863-866
Number of pages	4
Journal	Leukemia
Volume	35
Issue number	3
DOIs	https://doi.org/10.1038/s41375-020-0946-2
Publication status	Published - Mar 2021

Access to Document

10.1038/s41375-020-0946-2

Cite this

@article{659b3b92a02247ee9178c3bfbd762d89,

title = "Acute lymphoblastic leukemia and down syndrome: 6-mercaptopurine and methotrexate metabolites during maintenance therapy",

author = "{on behalf of the Nordic Society of Paediatric Haematology and Oncology (NOPHO)} and Anna {\O}stergaard and Cathrine Bohnstedt and Kathrine Grell and Matilda Degn and Bernward Zeller and Mervi Taskinen and Solveig Hafsteinsdottir and Helga Bj{\"o}rgvinsd{\'o}ttir and Mats Heyman and Peter Hoogerbrugge and Kjeld Schmiegelow",

note = "Funding Information: Acknowledgements This study has received financial support from: The Danish Cancer Society (Grant nos: 91-048, 92-017, 93-017, 95- erythrocytes. b DNA–TG: incorporated thioguanine nucleotides in leukocyte DNA. c MeMP: methylated 6–mercaptopurine metabolites in erythrocytes. Funding Information: 100-28, R19-A984, R214-A12962), The Otto Christensen Foundation, The Swedish Childhood Cancer Foundation (Grant nos. 53/91, 62/94, 72/96, 98/59), The Lundbeck Foundation (Grant no. 38/99) and The Danish Childhood Cancer Foundation. Thanks to the Nordic Society of Pediatric Hematology and Oncology for their participation in this study.",

year = "2021",

month = mar,

doi = "10.1038/s41375-020-0946-2",

language = "English",

volume = "35",

pages = "863--866",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - Acute lymphoblastic leukemia and down syndrome

T2 - 6-mercaptopurine and methotrexate metabolites during maintenance therapy

AU - on behalf of the Nordic Society of Paediatric Haematology and Oncology (NOPHO)

AU - Østergaard, Anna

AU - Bohnstedt, Cathrine

AU - Grell, Kathrine

AU - Degn, Matilda

AU - Zeller, Bernward

AU - Taskinen, Mervi

AU - Hafsteinsdottir, Solveig

AU - Björgvinsdóttir, Helga

AU - Heyman, Mats

AU - Hoogerbrugge, Peter

AU - Schmiegelow, Kjeld

N1 - Funding Information: Acknowledgements This study has received financial support from: The Danish Cancer Society (Grant nos: 91-048, 92-017, 93-017, 95- erythrocytes. b DNA–TG: incorporated thioguanine nucleotides in leukocyte DNA. c MeMP: methylated 6–mercaptopurine metabolites in erythrocytes. Funding Information: 100-28, R19-A984, R214-A12962), The Otto Christensen Foundation, The Swedish Childhood Cancer Foundation (Grant nos. 53/91, 62/94, 72/96, 98/59), The Lundbeck Foundation (Grant no. 38/99) and The Danish Childhood Cancer Foundation. Thanks to the Nordic Society of Pediatric Hematology and Oncology for their participation in this study.

PY - 2021/3

Y1 - 2021/3

UR - http://www.scopus.com/inward/record.url?scp=85087442484&partnerID=8YFLogxK

U2 - 10.1038/s41375-020-0946-2

DO - 10.1038/s41375-020-0946-2

M3 - Article

C2 - 32623444

AN - SCOPUS:85087442484

SN - 0887-6924

VL - 35

SP - 863

EP - 866

JO - Leukemia

JF - Leukemia

IS - 3

ER -